Coronel, Jenny

Jennifer Coronel


Associate

 

Overview

Jennifer Coronel is an associate in the Chicago office of Locke Lord LLP where she handles complex intellectual property litigation matters with a focus on Hatch-Waxman pharmaceutical patent issues. Her Hatch-Waxman experience includes the pre-litigation stage, including the preparation of Paragraph IV notice letters, as well as the stages of fact discovery, claim construction, expert discovery, and pre-trial.

While attending Northwestern University School of Law, Jennifer held externships with the U.S. District Court for the Northern District of Illinois for Judge Joan H. Lefkow, Northwestern University School of Law’s Bluhm Legal Clinic (Children and Family Justice Center), and the Cook County State’s Attorney’s Office (Felony Trial Division).

Representative Experience

  • Representing generic drug manufacturer in Paragraph IV Hatch-Waxman patent infringement litigation concerning an oral formulation for treating Type II diabetes (Farxiga® / dapagliflozin).
  • Representing generic drug manufacturer in Paragraph IV Hatch-Waxman patent infringement litigation concerning an oral formulation for treating certain types of psoriasis and psoriatic arthritis (Otezla® / apremilast).
  • Representing generic drug manufacturer in Paragraph IV Hatch-Waxman patent infringement litigation concerning an oral formulation for treating multiple myeloma (Revlimid® / lenalidomide).
  • Representing generic drug manufacturer in Paragraph IV Hatch-Waxman patent infringement litigation concerning a transdermal system for the treatment of Parkinson’s disease and restless legs syndrome (Neupro® / rotigotine).
  • Representing generic drug manufacturer in Paragraph IV Hatch-Waxman patent infringement litigation concerning an oral formulation for treating overactive bladder (Myrbetriq® / mirabegron).
  • Represented generic drug manufacturer in Paragraph IV Hatch-Waxman patent infringement litigation concerning an oral formulation for treating prostate cancer (Xtandi® / enzalutamide). Resolved matter through settlement.
  • Represented generic drug manufacturer in Paragraph IV Hatch-Waxman patent infringement litigation concerning an oral formulation for treating chronic obstructive pulmonary disease (Daliresp® / roflumilast). Resolved matter through settlement.
  • Represented generic drug manufacturer in Paragraph IV Hatch-Waxman patent infringement litigation concerning extended release capsules for treating certain types of seizes (Trokendi XR® / topiramate). Resolved matter through settlement.

Professional History

  • Associate, Locke Lord LLP (2016 - present)
  • Associate, Brinks Gilson & Lione (2014 - 2016)